SCHEMBL4167756

SCHEMBL4167756

COc1cc[c]c(-c2ccc(OC)c(OC)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
PDE4A P27815 2/20 0.49
ABCB1 P08183 2/20 0.44
PTGS2 P35354 1/20 0.42
PDGFRB P09619 1/20 0.41
PDGFRA P16234 1/20 0.41
MAPT P10636 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
CYP19A1 P11511 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
THRB P10828 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8527442 0.85 PDE4A (0.45) PDE4AMAPTNPC1RAB9AKDM4E
SCHEMBL8531984 0.83 ACHE (0.52) CA12CA1CA2CA7CA9
SCHEMBL459934 0.82 CA12 (0.44) CA12CA1CA2CA7CA9
SCHEMBL15066961 0.79 ALDH1A1 (0.41) CA12CA1CA2CA7CA9
SCHEMBL323109 0.79 DYRK1A (0.49) CA1CA2CA7CA9ABCB1
SCHEMBL5622659 0.79 ACHE (0.45) PDGFRBPDGFRAMAPTNPC1RAB9A
SCHEMBL8529256 0.78 CYP1A1 (0.45) ABCB1NPC1RAB9AALDH1A1
SCHEMBL8089523 0.78 CYP1A2 (0.53) PTGS2NPC1RAB9ACYP19A1KDM4E
SCHEMBL8529054 0.78 AHR (0.42) PDGFRBPDGFRA
SCHEMBL8563667 0.78 FYN (0.45) CA2PDE4ANPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118286-A1 Heterobicyclic Acrylamides BAYER CROPSCIENCE AG (DE) 2009-05-07 US claimed
EP-0690856-A4 UNIV NEW YORK (US) 1996-02-07 EP claimed
EP-0690856-A1 ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1996-01-10 EP claimed
WO-1994022856-A1 ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) 1994-10-13 WO claimed
EP-0129128-B1 2-PYRIMIDINYL-1-PIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM Troponwerke GmbH & Co. KG (DE) 1990-11-22 EP claimed
US-5749925-A Dyeing or printing process with new and known cationic 4,5-dihydro-iH-1,2,3-triazolium compounds as dyestuffs and new cationic 4,5-dihydro-1H-1,2,3-triazolium compounds BAYER AKTIENGESELLSCHAFT (DE) 1998-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118286-A1 Heterobicyclic Acrylamides CCNB1, C3AR1, CCNA2 CA12 4326/4885CA1 2650/4885CA2 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.